Healthcare / Medical Instruments & SuppliesKOSDAQ
$14170.00
-710.00 (-4.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $10.3B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$182.4B
P/E
N/A
•EV/EBITDA
33.0x
↑ROE
-0.7%
↓Gross Margin
67.2%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.7%
FCF CAGR
—
FCF margin
7.1%
FCF / Net income
-8.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $164.08B · net income $-1.36B · FCF $11.59B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $164.08B | $164.08B | $119.65B | $155.82B | $131.31B |
| Net Income | $-1.36B | $-1.36B | $-41.32B | $3.31B | $-20.46B |
| EBITDA | $7.01B | $7.01B | $-33.43B | $30.41B | $-2.91B |
| EPS | -100.00 | -100.00 | -2865.00 | 227.00 | -1380.00 |
| Gross Margin | 67.2% | 67.2% | 61.7% | 72.6% | 68.2% |
| Operating Margin | 6.2% | 6.2% | -34.0% | 13.4% | -3.4% |
| Net Margin | -0.8% | -0.8% | -34.5% | 2.1% | -15.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.42 | 0.61 | 0.70 |
| Current Ratio | 1.60 | 1.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $11.59B | $11.59B | $10.34B | $-618.7M | $-13.55B |
| Returns | |||||
| ROE | -0.7% | -0.7% | -20.2% | 1.7% | -12.3% |
| Valuation | |||||
| P/E | — | — | — | 102.64 | — |
| EV/EBITDA | 33.04 | 33.04 | — | 14.77 | — |
| P/B | 1.01 | 1.01 | 1.18 | 1.75 | 1.72 |
| Growth & Yield | |||||
| Revenue Growth | 37.1% | 37.1% | -23.2% | 18.7% | — |
| EPS Growth | 96.5% | 96.5% | -1362.1% | 116.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2865.00 → -100.00
Residual
-26.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.